This application is for the continuance of R37GM54060, a Merit Award initially awarded as an ROI in 1994. The purpose of this grant is to determine how LPS recognition results in the syndrome of Gram-negative sepsis. The current cycle proposed four Specific Aims: 1) To characterize MD-2, 2) To characterize the fine details of TLR4/MD-2 receptor activation, 3) To characterize the TLR4 adapters: MyD88, Mai, TRIP and TRAM, 4) To define the biology of MD-2 in vivo. We have published 17 papers attributable to R37GM54060 so far in this funding cycle, and addressed most of the major issues in its Aims. We have reported on the opsonic activity of MD-2 and worked out the fine details of TLR4/MD-2 receptor activation. We have characterized important aspects of MyD88 and Mai interaction and function. We have definitively addressed the issue of altemative LPS receptors in macrophages. We have yet to generate a Mab to MD-2, although immunizations are in progress. We will launch our studies on the in vivo role of MD-2 in sepsis when mAbs are available. Several studies with respect to the adapter molecules are in progress. In the next 5 years, two new Aims are proposed. First, we plan to begin a new project designed to define the exact role of LPS in sepsis using a systems biology approach. We will begin by infecting a panel of knockout mice, each deficient in a major immune signaling pathway (e.g., MyD88, TRIP, Unc93b, ASC, etc) with a strain of Y pestis in which the acylation pattern of lipid A, as well as the bioactivity, is genetically controlled. LPS from a recombinant strain that is proinflammatory will also be tested vs. the far less inflammatory wild-type LPS. By examining gene expression and cytokine expression in these infected or LPS challenged mice, we will draw an INNATE IMMUNE RESPONSE MAP. Those pathways effected by LPS will be identified and separated from signaling pathways activated in infection independently of LPS. Finally, we will perform forward genetic screening on wild-derived inbred mice to identify new genes involved in LPS responses and use this to refine our Innate Immune Response Map. We believe that these studies will identify those aspects of septic shock that are amenable to anti-LPS therapy in order to help reduce the mortality associated with septic shock.

Public Health Relevance

Gram-negative bacterial sepsis is a syndrome seen after infection with Gram-negative bacteria that can cause life threatening shut down of vital organs. Sepsis is a form of blood poisoning that we think is due to lipopolysaccharide, a lipid made by the cell walls of the bacteria. In this proposal, we seek to define how lipopolysaccharide causes this organ failure and ways in which we can reverse its toxic activity.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37GM054060-19
Application #
8686870
Study Section
No Study Section (in-house review) (NSS)
Program Officer
Dunsmore, Sarah
Project Start
1997-01-01
Project End
2018-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
19
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Worcester
State
MA
Country
United States
Zip Code
01655
Kalantari, Parisa; Harandi, Omid F; Agarwal, Sarika et al. (2017) miR-718 represses proinflammatory cytokine production through targeting phosphatase and tensin homolog (PTEN). J Biol Chem 292:5634-5644
Andrade, Warrison A; Agarwal, Sarika; Mo, Shunyan et al. (2016) Type I Interferon Induction by Neisseria gonorrhoeae: Dual Requirement of Cyclic GMP-AMP Synthase and Toll-like Receptor 4. Cell Rep 15:2438-48
Shaughnessy, Jutamas; Gulati, Sunita; Agarwal, Sarika et al. (2016) A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. J Immunol 196:1732-40
Ní Cheallaigh, Clíona; Sheedy, Frederick J; Harris, James et al. (2016) A Common Variant in the Adaptor Mal Regulates Interferon Gamma Signaling. Immunity 44:368-79
Tzeng, Te-Chen; Schattgen, Stefan; Monks, Brian et al. (2016) A Fluorescent Reporter Mouse for Inflammasome Assembly Demonstrates an Important Role for Cell-Bound and Free ASC Specks during In Vivo Infection. Cell Rep 16:571-582
Yang, Huan; Wang, Haichao; Ju, Zhongliang et al. (2015) MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med 212:5-14
Davaro, Facundo; Forde, Sorcha D; Garfield, Mark et al. (2014) 3-Hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin)-induced 28-kDa interleukin-1? interferes with mature IL-1? signaling. J Biol Chem 289:16214-22
De la Fuente, Marjorie; Franchi, Luigi; Araya, Daniela et al. (2014) Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome. Int J Med Microbiol 304:384-92
Janssen, Erin; Ozcan, Esra; Liadaki, Kyriaki et al. (2014) TRIF signaling is essential for TLR4-driven IgE class switching. J Immunol 192:2651-8
Levitz, Stuart M; Golenbock, Douglas T (2012) Beyond empiricism: informing vaccine development through innate immunity research. Cell 148:1284-92

Showing the most recent 10 out of 22 publications